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Background: The primary focus of research in schizophrenia has been on the positive symptoms, with ﬁnd-
ings that clearly establish their economic burden. More recently, research has expanded to focus on another
core symptom of schizophrenia, namely cognitive impairments. While this work has established the adverse
impact of cognitive impairments associated with schizophrenia (CIAS) on functional outcomes, their rela-
tionship to the economic impact of schizophrenia has not been systematically evaluated.
Objective: The aim of this research was to perform a systematic literature review identifying evidence that
evaluates: 1) the economic impact of CIAS and its treatments, including health-state utilities, and 2) the eco-
nomic evidence associated with improvements in the Measurement and Treatment Research to Improve Cog-
nition in Schizophrenia (MATRICS) Consensus Cognitive Battery and the University of California Performance
Skills Assessment (UPSA).
Method: A systematic search of articles published from January 1999–April 2013 was conducted. Studies
reporting direct costs, indirect costs, and quality of life impacts of CIAS and costs of CIAS interventions
were reviewed.
Results: Forty-three studies met inclusion criteria. Twenty-four focused on indirect costs (work-related out-
comes) associated with cognitive impairments and 14 studies included residential status outcomes. Four
studies concentrated on the direct cost of cognitive remediation therapy. Three studies reported quality of
life outcomes, but none used health-state utilities. Eight studies focused on the UPSA and its relationship
to community outcomes. Only two studies were cost-effectiveness analyses.
Conclusions: Despite the growing scientiﬁc literature relating CIAS to adverse outcomes, the translation of
outcomes into economic outcomes is seldom reported. Should novel pharmacotherapies and/or psychosocial
treatments require reimbursement from health authorities and/or other payers, many gaps warrant attention
in order to demonstrate the economic value of these therapies.© 2014 Elsevier Inc. All rights reserved.1. Introduction
The current approaches to pharmacological treatment of patients
with schizophrenia are based upon stabilization of psychotic symptoms
through the use of antipsychotic therapies. The ability of ﬁrst- and
second-generation antipsychotics to stabilize patients and to reduce
the incidence of costly relapse is well-documented. (Leucht et al.,
2012) Moreover, the literature is replete with studies evaluating differ-
ential effectiveness and cost-effectiveness within the array of treat-
ments administered to patients with schizophrenia for treatment of
psychotic symptoms. (Ascher-Svanum et al., 2009; Edwards et al.,
2005; Furiak et al., 2009; Heeg et al., 2005) However, two other core
symptoms of schizophrenia also merit economic analysis, cognitive im-
pairment and negative symptoms, because these symptoms may alsocago, IL 60064. Tel.: + 847 938
rights reserved.represent manifestations signiﬁcantly associated with the cost of the
illness. The focus of this paper is the body of literature documenting
the economics of cognitive impairment associated with schizophrenia
(CIAS) and its treatments.
Nearly every patient with schizophrenia experiences a cognitive
decrement from the premorbid state. (Keefe, 2008; Keefe et al.,
2005; Manschreck and Boshes, 2007) Even patients with neuropsy-
chological test scores similar to healthy controls have comparatively
lower mean functional performance scores. (Keefe et al., 2005;
Kremen et al., 2000) There is an extensive literature documenting
the aspects of function (e.g., social functioning, residential, occupa-
tional functioning, and quality of life) associated with CIAS. Studies
of patients with other psychiatric disorders have documented differ-
ences in costs and economic burden in patients who do, versus who
do not, have cognitive impairments (e.g., Mackin et al., 2011). Re-
search in patients with schizophrenia has shown that those with
higher functional and cognition scores predictably achieve signiﬁcant
employment and residential milestones, such as independent living
Table 1
PubMed search strategy (also customized for Embase, Medline In-Process, The
Cochrane Library, and clinicaltrials.gov).
Search
#
Term
1 (schizophrenia[MeSH]) AND (“cognitive deﬁcit syndrome” OR cognition
OR cognitive OR “cognitive impairment” OR neurocognition OR
neurocognitive)
2 #1 limited to: editorial, letter, comment, case report
3 #1 NOT #2
4 #3 limited to: animals
5 #3 NOT #4
6 #5 AND (economic OR cost-effectiveness OR cost⁎ OR burden OR pro-
ductivity OR value OR societal OR ﬁnancial OR resource OR absenteeism
OR disability OR employment OR vocational OR occupational OR expen-
diture OR “quality-adjusted life years” OR residential)
⁎ truncated term.
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whether improving cognition results in economic beneﬁts remains
and has yet to be examined systematically, largely because of the
lack of currently available effective treatments.
There is evidence supporting the clinical beneﬁts of cognitive re-
mediation therapy (CRT), in both conventional and computerized for-
mats. (Patel et al., 2010; Wykes et al., 2007) However, these beneﬁts
were realized only when added to another form of psychiatric reha-
bilitation (e.g., supported employment, strategy training) versus
adding CRT to usual care. (McGurk et al., 2007; Wykes et al., 2011)
Cognitive remediation methods are still developing, and there re-
mains uncertainty over which techniques should be employed and
whether the outcomes are beneﬁcial in terms of sustained effects on
cognition or improved functioning. (National Institute for Health
and Clinical Excellence, 2009) Due to variability in methodological
rigor of the studies and the observed effectiveness of cognitive reme-
diation, further research is required.
In addition to psychosocial treatments, pharmacotherapies have
also been identiﬁed as potentially viable options for improving cogni-
tion. In recognition of the need to facilitate the study and registration
of pharmacologic agents for the treatment of CIAS, the US National In-
stitute of Mental Health (NIMH) developed an initiative called “Mea-
surement and Treatment Research to Improve Cognition in
Schizophrenia” (MATRICS). In partnership with the US Food and
Drug Administration (FDA), industry, and academia, NIMH developed
and published a consensus statement regarding how pharmacologic
agents for the treatment of CIAS may be assessed (http://www.
matrics.ucla.edu/matrics-recommendations.shtml). The MATRICS
task force developed the MATRICS Consensus Cognitive Battery
(MCCB) and selected it, along with a performance-based measure:
the University of California Performance Skills Assessment (UPSA),
as co-primary trial outcomes for evaluation of new therapies. Demon-
strating beneﬁt according to these measures is the ﬁrst step in
establishing the efﬁcacy of novel pharmacotherapies to treat CIAS.
In addition to meeting efﬁcacy hurdles, new therapies for CIAS will
have to meet an array of economic expectations and demonstrate
value for money in order for them to be reimbursed and made avail-
able to patients in need of treatment. The pursuit of economic evi-
dence in parallel with efﬁcacy assessments is critical due to
decreases in the availability of health care funds. Understanding the
current state of economic evidence regarding CIAS and its treatments
is a prerequisite for establishing a foundation of knowledge from
which to build future research. The aim of this study was to perform
a systematic literature review to identify evidence evaluating: 1)
the economic impact of CIAS and its treatments, including their im-
pact on health-state utilities, and 2) the economic evidence associat-
ed with improvements in the Measurement and Treatment Research
to Improve Cognition in Schizophrenia (MATRICS) Consensus Cogni-
tive Battery and the University of California Performance Skills As-
sessment (UPSA).
2. Methods
Systematic searches of English language articles published from
January 1999 through April 2013 were conducted in multiple data-
bases: PubMed, EMBASE, MEDLINE In-Process & other Non-Indexed
Citations, EconLit, PsycINFO, and Clinicaltrials.gov. Abstracts from sci-
entiﬁc conferences were also searched including: Schizophrenia In-
ternational Research Society (SIRS), International Congress on
Schizophrenia Research (ICOSR); American College of
Neuropsychopharmacology (ACNP); European College of
Neuropsychopharmacology (ECNP), Mt. Sinai Conference on Cogni-
tion in Schizophrenia, the European Conference on Schizophrenia Re-
search, American Psychological Association, and the International
Society of Pharmacoeconomics Research (ISPOR). Articles before
1999 were excluded because, before that time, there was limitedevidence regarding cognitive impairments, their functional conse-
quences or appropriate interventions to address them. (Green,
1996; Bellack et al., 1999).
The literature search terms were developed to capture studies
providing pharmacoeconomic information on direct and indirect
costs, quality of life assessments associated with CIAS, as well as
costs of CIAS treatments. Direct costs are deﬁned as those incurred
for medical treatment, such as visits with a physician, emergency
room costs, hospitalization costs, community mental health costs,
etc. Indirect costs are those associated with lost productivity/work
due to patient disability, lost productivity/work by caregivers, societal
costs (e.g., incarceration), etc. Literature regarding quality of life was
included because of the importance of these measures in the calcula-
tion of the quality adjusted life year (QALY), which is widely used as
the denominator of cost-effectiveness ratios in economic analyses.
For several countries, this metric is a critical component of evalua-
tions that determine reimbursement for new pharmaceutical
therapies.
The literature included in this review was speciﬁc to that dealing
with economic, societal, residential and occupational outcomes of pa-
tients with schizophrenia. The structure of the ﬁnal search strategy
for PubMed, including search terms and limits, is shown in Table 1
with references from search #6 being saved for review. This strategy
was adapted for searches in the additional databases listed above.
References from these searches were then reviewed using the inclu-
sion and exclusion criteria detailed in Table 2.
Included studies were required to contain at least one reference to
direct costs, indirect costs, costs associated with cognitive therapies
or quality of life measurement. Reference lists of included studies
were also reviewed for additional potentially relevant studies. Includ-
ed studies were assessed for similarities with respect to study design,
treatment examined (if any), and outcomes evaluated. Results of
studies with similar outcomes/treatments were compared. Included
studies were also assessed chronologically to determine how research
in this area has evolved over time.3. Results
Table 3 displays the characteristics of the 43 included studies.
Twenty-four of these studies focused on work-related effects of cog-
nitive deﬁcits, such as wages earned, hours worked, employment sta-
tus, and patient level predictors (PLPs) of employment (column 7 of
Table 3). Four studies concentrated on cost-related outcomes of
CRT. There were three studies reporting quality of life (QoL) out-
comes, but none of these assessed QoL using health-state utilities.
Nine of the included studies focused on the ability of UPSA to identify
patients most likely to achieve improved functional milestones. Of the
43 studies, nine were randomized-controlled trials (RCTs), 32 had an
Table 2
Inclusion and exclusion criteria.
Inclusion criteria
• Publication in which the area of interest is cognition in schizophrenia
• Studies providing information on the following topics:
○ Direct costs
○ Indirect costs
○ Costs associated with cognitive therapies
Exclusion criteria
• Non-English – articles where only the abstract is in English (but the publication
was not)
• Opinion-based – articles including, but not limited to, editorials, comments,
non-systematic reviews, and letters
• Disease state – studies that do not focus on cognition in schizophrenia
• Case study – articles describing case studies and/or case reports
• Withdrawn – studies that were published and subsequently withdrawn
• In vitro/animal studies – studies conducted in vitro or in animals
(e.g., rats, pigs, mice, etc.) rather than in humans
• Not an outcome of interest – trials that did not report economic outcomes
• Outside of time parameters – articles that were published prior to the
inclusion years
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two were cost-effectiveness analyses (CEA).
3.1. Employment outcomes
An early study of the impact of CIAS on employment outcomes
was conducted by McGurk and colleagues, focusing on associa-
tions between neurocognitive functioning and employment status
(i.e., full-time, part-time, unemployed) (2000). Univariate analyses
indicated that level of cognitive functioning was the most impor-
tant difference between the three employment groups, with the
full-time employed group performing better than the other groups
on every cognitive domain assessed. Differences were also found,
depending on the cognitive domain evaluated, between the full-
time and part-time groups and the part-time and unemployed
groups. In subsequent research, McGurk and colleagues evaluated
predictors of work outcomes (e.g., sustained employment) in a
supported employment setting over a two-year period. (McGurk
et al., 2003) Results indicated that higher levels of cognition, vary-
ing by type of cognition assessed, were associated with higher
wages earned and hours worked. They then examined this cohort
over an additional two-year period, for a total of four years of ob-
servation. (McGurk and Mueser, 2006) Analyses suggested that
cognitive functioning was even more predictive of wages earned
and hours worked during the latter two years of the study than
in the ﬁrst two years. Furthermore, patients with lower levels of
cognition required more hours of job support and a higher num-
ber of employment specialist contacts.
Other researchers have also found associations between cognitive
deﬁcits and work and employment outcomes. These studies generally
found signiﬁcant associations between cognitive functioning and cur-
rent and past employment. (Gould et al., 2013; Jaeger et al., 2006;
Rosenheck et al., 2006; Verdoux et al., 2010) Additionally, cognitive
impairment was linked to cooperativeness, work habits, work quality,
social skills and personal presentation as measured by the Work Be-
havior Inventory. (Bell and Bryson, 2001) Furthermore, cognitive
functioning was found to be predictive of endpoints such as vocation-
al functioning, obtaining competitive employment and capability to
work, as well as poorer work performance (Bowie et al., 2010;
Evans et al., 2004; Giugiario et al., 2012; Hoffmann et al., 2003;
Lysaker et al., 2002; Mausbach et al., 2011).
Not all studies have supported the connection between CIAS and
employment outcomes. Srinivasan and Tirupati (2005) found cogni-
tive deﬁcits were not signiﬁcantly related to work status or perfor-
mance. This study examined a relatively small number of patients
(n=88) and was performed on patients from a specializedrehabilitation center in a large city with potentially better employ-
ment opportunities and access to successful work rehabilitation.
Krishnadas et al. also failed to ﬁnd a signiﬁcant correlation between
cognitive function and disability in a sample of schizophrenia patients
from India. (Krishnadas et al., 2007) A large portion (75%) of patients
in this study remained employed despite cognitive deﬁcits. This pat-
tern of results was similar to those of other studies from India, indi-
cating potential socio-cultural factors. (Thara, 2004).
Trials investigating the impact of interventions targeting cognition
(e.g., CRT, neurocognitive enhancement therapy) alone or in conjunc-
tion with other psychosocial interventions (e.g., supported employ-
ment) have found robust improvements in employment outcomes
with treatment. Improvement in employment outcomes such as
number of hours and/or weeks worked (Bell et al., 2008, 2005
McGurk et al., 2009, 2007, 2005; Wexler and Bell, 2005) and higher
wage earnings (Bell et al., 2005; Eack et al., 2011; McGurk et al.,
2009, 2007) are strongly supported in this literature. Support has
also been found for the impact of these interventions on the ability
to maintain employment or achieve a higher rate of competitive-
wage employment (Bell et al., 2005, 2008; Eack et al., 2011; McGurk
et al., 2005), successful job placement (Vauth et al., 2005), and satis-
faction with employment status. (Eack et al., 2011).
3.2. Residential outcomes
Several studies found cognitive functioning to be predictive of res-
idential status. (Leung et al., 2008; Mausbach et al., 2007, 2008;
Twamley et al., 2002) Cognitive impairment was found to be associat-
ed with poorer performance of activities of daily living and ability to
live independently. (Gupta et al., 2003; Harvey et al., 2009; Jaeger et
al., 2006; Mausbach et al., 2010, 2011 Self-assessment of functional
ability was associated with both residential independence and ﬁnan-
cial responsibility. (Gould et al., 2013).
3.3. Quality of life
We were not able to identify any studies that discussed quality-
adjusted life years in studies of CIAS. While not speciﬁcally a focus
of this research, other measures of quality of life were noted in the lit-
erature accessed for this study. Conﬂicting results were noted, with
self-reported QoL (World Health Organization Quality of Life-BREF)
being unrelated to cognitive functioning. (Hofer et al., 2005) Howev-
er, a signiﬁcant correlation was reported between cognitive impair-
ment and poorer QoL as measured by the disease-speciﬁc Quality of
Life Scale, an interview-based assessment. (Lipkovich et al., 2009;
Savilla et al., 2008).
3.4. Studies examining cost of care
Those studies that included an assessment of direct costs were
conducted in the UK. Patel et al. found a signiﬁcant relationship be-
tween higher cognition scores (better) and lower total costs (85% of
which were direct costs) from a UK societal perspective. (Patel et
al., 2006) In a study of direct costs associated with CRT intervention,
Wykes et al. (2003) found increased day care costs associated with
CRT, but inferred that increased use of day care may provide impor-
tant beneﬁts such as improved social function and QoL. These authors
subsequently conducted a CEA of CRT showing reduced cost and im-
proved outcomes at the end of treatment, but a small increase in
cost at follow-up despite a durable beneﬁt of improved memory.
(Wykes et al., 2007) This observation was conﬁrmed in a subsequent
2010 analysis comparing the cost-effectiveness of CRT plus usual care
to usual care alone at both short-term (14 weeks) and medium-term
(40 weeks) treatment periods. (Patel et al., 2010) Neither total
health/social care nor societal costs were different between the two
treatment groups at either time period. The mean cost difference
Table 3
Summary of included studies.
Study Duration N Study Design Study Aim/Objective Economic Outcomes
Assessed
1 (Dickerson et al., 1999) N/A 72 Cross-sectional To identify factors that predict degree of residential independence Residential status
2 (McGurk and Meltzer,
2000)
N/A 30 Cross-sectional To evaluate the relationship between neurocognitive functioning
and occupational status in schizophrenia patients with stable work
status (full-time, part-time, unemployed)
Employment
3 (Bell and Bryson, 2001) 26 weeks 33 Single-arm trial To evaluate the contribution of cognitive impairment on rate of
work rehabilitation
Employment
4 (Roder et al., 2001) 12
months
73 Prospective
cohort
To test the efﬁcacy of 3 skills training programs in the residential,
vocational, and recreational domains
Residential status
and employment
5 (Auslander et al., 2001) N/A 251 Cross-sectional To compare living status with standardized measures of
psychopathology, cognition and health-related quality of
wellbeing, and determine predictors of living status
Residential status
6 (Lysaker et al., 2002) 7 weeks 121 Prospective
cohort
To evaluate whether measures of insight predict performance in a
work rehabilitation program
Employment, PLPs
7 (Twamley et al., 2002) N/A 111 Cross-sectional To examine the relationship between the UPSA and cognitive
functioning and living status
Residential status
8 (McGurk et al., 2003) 2 years 30 Single-arm trial To examine the relationship of cognitive functioning and clinical
symptoms with competitive employment outcomes for patients
in a supported employment program
Employment, PLPs
9 (Hoffmann et al., 2003) N/A 53 Cross-sectional To test outcome predictors of functioning in patients enrolled in
a vocational rehabilitation program
Employment, PLPs
10 (Wykes et al., 2003) 6 months 33 RCT To test the durability of the effects of CRT vs. intensive occupational
therapy (control) 6 months after therapies were withdrawn. Data
on use of services and costs of therapy were also collected
Direct costs
11 (Gupta et al., 2003) N/A 85 Cross-sectional To examine the effect of symptom severity and cognitive
impairment on living status
Residential status
12 (Evans et al., 2004) 4 months 112 Prospective
cohort
To examine the relationship of cognitive functioning and clinical
symptoms with vocational outcomes and identify predictors
Employment, PLPs
13 (Hofer et al., 2005) N/A 60 Cross-sectional To assess the relationship of cognitive deﬁcits and treatment
outcomes in terms of QoL, needs, and psychosocial functioning
PLPs, QoL
14 (Vauth et al., 2005) 1 year 138 RCT To evaluate the effects of CAST + vocational rehabilitation vs.
TSSN + Vocational rehabilitation vs. Vocational rehabilitation alone
Employment
15 (Bell et al., 2005) 1 year 145 RCT To evaluate productivity outcomes after 6 and 12 months of work
therapy vs. NET + work therapy
Employment
16 (Srinivasan and Tirupati,
2005)
N/A 88 Cross-sectional To examine the relationship between work functioning and
cognition, clinical and demographic variables, and social functioning
Employment
17 (McGurk et al., 2005) 1 year 44 RCT To examine the effectiveness of cognitive training + supported
employment vs. supported employment for improving competitive
employment outcomes
Employment
18 (Wexler and Bell, 2005) N/A Literature review To review past work demonstrating that cognitive remediation
treatment with work therapy or supported employment has lasting
improvements in cognition and work functioning
Employment
19 (Rosenheck et al., 2006) N/A 1438 Undetermined To evaluate factors associated with participation in competitive
employment, participation in other employment activities, and
earnings of those employed
Employment
20 (Patel et al., 2006) 6 months 85 Retrospective
cohort
To examine the associations between cognition and costs in
patients with schizophrenia
Direct and indirect costs
21 (McGurk and Mueser,
2006)
4 years 30 Single-arm trial To evaluate the long-term association of cognitive impairment and
work outcomes
Employment, PLPs
22 (Jaeger et al., 2006) 18
months
250 Prospective
cohort
To determine association of cognitive proﬁle with functional
outcomes
Residential status
and employment
23 (McGurk et al., 2007) 3 years 44 RCT To evaluate long-term employment and hospitalization outcomes
of supported employment vs. supported employment + cognitive
training
Employment
24 (Wykes et al., 2007) 40 weeks 85 RCT To evaluate the effectiveness of CRT vs. treatment as usual Direct and indirect costs,
CEA (memory
improvement/cost)
25 (Niekawa et al., 2007) N/A 47 Controlled
observational
study
To examine ﬁnancial competence in patients with schizophrenia
and the relationship between ﬁnancial competence and cognitive
function
Financial competence
26 (Krishnadas et al., 2007) N/A 50 Cross-sectional To compare neurocognitive functioning between patients with
schizophrenia and normal controls, and to determine a relationship
between cognition and functional disability
Employment
performance
27 (Mausbach et al., 2007) N/A 434 Cross-sectional To identify subscales for the UPSA-Brief and establish its initial
concurrent validity by demonstrating its relationship with other
measures of functioning
Residential status
28 (Mausbach et al., 2008) N/A 434 Cross-sectional To examine the sensitivity and speciﬁcity of the UPSA for prediction
of independent living status
Residential status
29 (Savilla et al., 2008) N/A 57 Cross-sectional To investigate the relationship between cognitive function,
symptoms, and QoL
QoL
30 (Bell et al., 2008) 2 years 72 RCT To determine the effect of NET vs. NET + supported employment on
functional outcomes
Employment
31 (Leung et al., 2008) N/A 238 Cross-sectional Residential status and
employment
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Table 3 (continued)
Study Duration N Study Design Study Aim/Objective Economic Outcomes
Assessed
To examine whether neuropsychological and cross-sectional
symptomatic status differentially predict elements of functional
outcome
32 (McGurk et al., 2009) 2 years 34 RCT To evaluate the effects of CRT + vocational rehabilitation vs.
vocational rehabilitation on cognitive functioning and work outcomes
Employment
33 (Lipkovich et al., 2009) 24 weeks 414 Retrospective
data analysis
To evaluate the relationship among cognition, psychopathology, and
psychosocial functioning
QoL
34 (Harvey et al., 2009) N/A 390 Cross-sectional To examined the similarity of performance-based assessments of ev-
eryday
functioning, real-world disability, and achievement of milestones
Residential status
35 (Patel et al., 2010) 40 wks 85 RCT To examine the costs and cost-effectiveness of usual care vs. usual
care + CRT
Direct and indirect
costs, CEA
(memory improvement/cost)
36 (Verdoux et al., 2010) 2 years 108 Prospective
cohort
To explore whether self-perceived cognitive deﬁcits predict
occupational outcomes
Employment
37 (Mausbach et al., 2010) N/A 205 Cross-sectional To examine the usefulness of the UPSA-B for prediction of
‘real-world’ functioning
Residential status
38 (Bowie et al., 2010) N/A 291 Cross-sectional To examine predictors of functional deﬁcits Employment, predictors
39 (Eack et al., 2011) 2 years 58 RCT To examine the effects of cognitive enhancement therapy vs.
enriched supportive therapy (control) on employment outcomes
Employment
40 (Mausbach et al., 2011) N/A 367 Cross-sectional To examine the sensitivity and speciﬁcity of the UPSA to predict
residential and employment status
Residential status and
employment
41 (Giugiario et al., 2012) N/A 253 Cross-sectional To examine the relationship among insight, psychopathology,
cognitive function, and competitive employment
Employment
42 (Gould et al., 2013) N/A 195 Cross-sectional To explore self-assessment accuracy and real-world functioning Residential status and
employment
43 (McClure et al., 2013) N/A 139 Cross-sectional To evaluate functional capacity and real-world functioning in
patients with SPD
Residential status and
employment
Abbreviations: CAST= Computer assisted cognitive strategy training, CEA= cost-effectiveness analysis, CRT= cognitive remediation therapy, NET= neurocognitive enhancement
therapy, QoL = quality of life, PLP = Patient-Level Predictors, RCT = randomized controlled trial, SPD = schizotypal personality disorder, TSSN = Training of self-management
skills for negative symptoms.
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ment, suggesting cost-savings due to CRT are realized in the short-
term, but not sustained. The authors hypothesized that this was due
to increased use of community/outpatient services.
3.5. Longitudinal trends
Table 3 lists the studies included in this analysis in chronological
order. In general, older studies focused on employment outcomes
and their predictors, but not the costs associated with them. After
2005, there was an increased focus on evaluating employment out-
comes in response to cognitive remediation therapies in randomized
trial settings and follow-up studies of increased duration (1–4 years).
One cost-effectiveness analysis from trial data was found from 2010,
quantifying cost-effectiveness as the additional cost of a 1% gain in
the number of patients improving working memory. Although anoth-
er study evaluated the relationship between quality of life and cogni-
tive function, none reported cost-effectiveness ratios as cost/quality
adjusted life year gained. Only one study reported changes in re-
source use given cognitive interventions compared to usual treat-
ment, nine studies included versions of UPSA, but none of the
studies assessed cognition using the MCCB. Studies evaluating func-
tional capacity in patients with schizophrenia (Table 3, rows 27–43)
suggest that increased functional capacity is correlated with greater
achievement of functional milestones in employment and indepen-
dent residential status.
4. Discussion
The objective of this research was to perform a systematic litera-
ture review to assess economic evaluations of the impact of CIAS
and its treatments. The search strategy yielded 43 studies published
between January 1999 and April 2013. Three of the studies used
costs as a key component of their analyses, with a fourth reportingthe added cost of CRT. Three of the selected studies attempted to eval-
uate quality of life, but none collected utility measurements from ei-
ther the perspective of the patient or society. Instead of the cost/
QALY metric typically used in cost-effectiveness studies, two studies
that reported cost-effectiveness ratios reported an alternative mea-
sure: Incremental cost for each 1% gain in the proportion of the pop-
ulation demonstrating an improvement in overall cognition.
Although some studies included measures that are part of the
MATRICS battery, none used these measures to evaluate the beneﬁts
of psychosocial cognitive interventions. Instead, the studies used a
vast array of methodologies, endpoints, and timeframes, making it
difﬁcult to draw deﬁnitive conclusions regarding the economic bene-
ﬁts of addressing cognitive impairments via interventions.
In recent years, the ﬁeld of pharmacoeconomics has grown in parallel
with the increasing demands by reimbursement authorities. New thera-
pies are expected to provide value for money and avoid substantial bur-
den to formulary or national health budgets. Government agencies such
as the National Institute for Health and Care Excellence (NICE) in the
United Kingdom, the Canadian Agency for Drugs and Technologies in
Health (CADTH), Scottish Medicines Consortium (SMC), and Institut für
Qualität in Germany have committed to cost, effectiveness, and cost-
effectiveness measures in evaluating new therapies. Each evaluates
new drugs in accordance with their healthcare budgets and societal
norms. In some cases, these agencies specify thresholds at which they
consider a new drug acceptable for reimbursement. These thresholds
are expressed as the incremental cost of an added therapy (versus cur-
rent standards of care) divided by the incremental gain in QALYs. In
the US, cost of care and other measures of beneﬁt, rather than cost/
QALY are considered in reimbursement decisions made by managed
care organization.
Current data on the direct costs associated with CIAS is limited and is
insufﬁcient to support economic modeling that would address the needs
of reimbursement authorities. An additional data gap identiﬁed through
this research is proper utility measurement for CIAS. Historically, utility
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schizophrenia have been collected from the patient perspective and/or
the perspective of persons not afﬂicted with the disease (sometimes re-
ferred to the “societal perspective” or the “layman’). In general, these
studies have shown that patients with schizophrenia evaluate the utility
of their health state higher than those in the societal realm, likely due to
patient-level factors such as a lack of awareness of their disease as it re-
lates to societal norms. Additionally, they may lack the cognitive ability
to understand the severity of schizophrenia in general. Briggs et al.
(2008) collected direct utility measures from patients and laypersons
and showed that patients rated the same health state descriptions higher
than laypersons. Their descriptions of health states hadmuch in common
with those found in an earlier study by Lenert et al. (Lenert et al., 2004)
who estimated societal utilities of similar magnitude. Therefore, it may
be critical to gather utility data from both perspectives to accommodate
differences across cultures.
Another factor in the approval of new pharmacological or psycho-
social treatments, especially for national European formularies, may
be assessments of cost savings to society in indirect costs through im-
provements in the lost productivity of patient and their caregivers.
Cost/QALY calculations may include a separate category with these
costs if properly documented, but in general, the direct cost offsets
of new therapies and cost/QALY estimates take precedence. Evidence
regarding the relationship of indirect cost to CIAS is perhaps the most
robust component of the literature at this time.
Perhaps most important for the development of new pharmaco-
therapies is advancing the level of evidence supporting the relation-
ship of the FDA endorsed MCCB and UPSA clinical trial endpoints to
direct costs, indirect costs and utilities. The MATRICS endorsed out-
come measures (MCCB, UPSA) are currently in use in late stage clini-
cal trials of new pharmacotherapies, so it is somewhat expected that
incremental economic gains associated with these metrics are not yet
available. Until these linkages are made, it will be difﬁcult to make
economic arguments via modeling in order to gain reimbursement
for CIAS interventions.
Future study of pharmacotherapies and psychotherapies to treat CIAS
could ﬁll the gaps identiﬁed by the results of this study if the design of
trials were to include key economic elements. Investigators anticipating
the challenges of demonstrating value for money for new pharmacother-
apies and psychosocial interventions need to systematically collect re-
source use, direct and indirect cost, and employment-related data. The
availability of these data would greatly enhance the base of knowledge
on CIAS interventions and the economic impact they may have. Equally
important is the collection of quality of life data (particularly utilities)
in anticipation of satisfying cost/QALY thresholds common in formulary
environments outside the US.
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